Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.50 |
| ▸ | HRH2 | P25021 | 10/20 | 0.49 |
| ▸ | HRH1 | P35367 | 10/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13320335 | 0.86 | EPHX2 (0.52) | EPHX2HRH2HRH1 | |
| SCHEMBL3986277 | 0.86 | HRH2 (0.46) | EPHX2HRH2HRH1 | |
| SCHEMBL215303 | 0.85 | EPHX2 (0.52) | EPHX2HRH2HRH1 | |
| SCHEMBL214527 | 0.84 | HRH2 (0.51) | EPHX2HRH2HRH1GPR119 | |
| SCHEMBL3583026 | 0.83 | TLR9 (0.49) | EPHX2HRH2HRH1 | |
| SCHEMBL216291 | 0.83 | EPHX2 (0.52) | EPHX2GPR119 | |
| SCHEMBL18910879 | 0.82 | EPHX2 (0.59) | EPHX2HRH2HRH1 | |
| SCHEMBL5935416 | 0.82 | MAOB (0.51) | EPHX2 | |
| SCHEMBL18910796 | 0.82 | EPHX2 (0.47) | EPHX2HRH2HRH1 | |
| SCHEMBL27677145 | 0.80 | FAAH (0.47) | EPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370372-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-06 | — | — | US | disclosed |
| WO-2017090719-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-06-01 | — | — | WO | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | EPHX2 2115/4885HRH2 884/4885HRH1 1368/4885 |
| US-10370372-B2 | Fused pyrimidine compound or salt thereof | AR, NR5A1, FSHR | EPHX2 2340/4885HRH2 2007/4885HRH1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.